Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi, BioNTech Form Cancer Pact
by Lisa M. Jarvis
November 9, 2015
| A version of this story appeared in
Volume 93, Issue 44
Sanofi will pay BioNTech, a German firm developing messenger RNA-based drugs, $60 million up front as part of a cancer immunotherapy collaboration. Under the multiyear pact, the companies will develop five cancer immunotherapies comprising a mixture of synthetic messenger RNAs. The deal comes as Sanofi tries to catch up to other big pharma firms working on immuno-oncology. In July, the French company sealed a multi-billion-dollar deal with Regeneron to develop immuno-oncology antibodies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X